Media

News

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS

Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN)...
Button Text

Lantern Pharma Announces Formation of Starlight Therapeutics

Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN)...
Button Text

Lantern Pharma Achieves Key Milestone Towards Development of Molecular

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical...
Button Text

Press Releases

Jul 10, 2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Button Text
May 29, 2025

Lantern Pharma's LP-184 (STAR-001) Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

Feb 19, 2025

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Nov 26, 2024

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 5, 2024

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Oct 15, 2024

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Sep 23, 2024

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers

Jan 17, 2024

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

Mar 6, 2023

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Videos

Aug 1, 2024

Starlight Therapeutics - Born from AI, Lighting the Way in CNS Cancer Treatment

June 26, 2024

STAR-001 in Multiple Brain and CNS Cancers

May 26, 2022

Brain Tumor Awareness Month GBM KOL Webinar

Aug 1, 2024

Starlight Therapeutics - Born from AI, Lighting the Way in CNS Cancer Treatment

June 26, 2024

STAR-001 in Multiple Brain and CNS Cancers

May 26, 2022

Brain Tumor Awareness Month GBM KOL Webinar